Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

AN ADAPTIVE PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY ASSESSING EFFICACY AND SAFETY OF SARILUMAB FOR HOSPITALIZED PATIENTS WITH COVID-19
Study of Sarilumab for Patients Hospitalized with COVID-19
Sponsor:Regeneron
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS9615
U.S. Government ID:NCT04315298
Contact: Brett Gray: 212-305-1570 / bg2168@cumc.columbia.edu
Additional Study Information:

The main purpose of this study is to determine if sarilumab is safe and if it can decrease the amount of time a person has COVID-19 symptoms. Sarilumab (also known as Kevzara ) is considered an investigational drug in this study because it has not been approved for marketing by any health authority for the condition being studied but it has been approved in multiple countries for active rheumatoid arthritis. Sarilumab is a type of drug called a monoclonal antibody. An antibody is a special kind of protein that one's immune (defense) system normally makes to fight bacteria and viruses. Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases. Sarilumab has been specifically shown to block the action of a protein called interleukin-6 (IL-6) in the body. Interleukin-6 (IL-6) is a protein in the immune system that has been shown to play an important role in inflammation. Inflammation may be associated with complications of COVID-19.

Do You Qualify?
Is the patient 18 years of age or older?YesNo
Has the patient tested positive for COVID-19?YesNo
Is the patient hospitalized and requiring care for COVID-19?YesNo
Submit
Cancel
Investigator
Magdalena Sobieszczyk, MD, MPH
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Brett Gray
Email: bg2168@cumc.columbia.edu
Phone: 212-305-1570